🏛️ Verified NIH Record • Updated 2026-03-12

Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome (NCT07273838)

Sodium-Glucose Cotransporter-2 Inhibitor for Amelioration of Acute Cardiorenal Syndrome: A Randomized Controlled Trial

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Yale University

🩺 Plain-English Summary (8th-Grade Level)

The overall objective of this study is to determine whether the addition of SGLT2 inhibitors to usual care in hospitalized patients with heart failure associated acute kidney injury is safe and efficacious. Investigators will assess if SGLT2 inhibition improves a composite cardio-renal outcome (mortality, dialysis, AKI progression, decongestion metrics, heart failure symptoms). Secondary objectives of this study are to compare individual components of the composite outcome as well as changes in biomarkers of kidney injury, inflammation, repair and oxidative stress between those exposed to the SGLT2 inhibitor vs placebo.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (19 items).

Location: Yale New Haven Hospital-St. Raphael Campus — New Haven, Connecticut

Age range: 18 Years to 85 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • AKI can be primarily explained by another etiology
  • Current use of SGLT2 inhibitor or exposure in the past 72 hours
  • Pregnancy or lactation (pregnancy test prior to enrollment in women of child-bearing age)
  • Known allergic reactions to components of an SGLT2 inhibitor
  • Treatment with another investigational drug for heart failure different from or in addition to usual care within the 72 hours preceding AKI
  • Any individual who meets any of the following criteria will be excluded from participation in this study:
  • Documented history of ileal conduit (neobladder)
  • No means of collecting urine such as patients with documented incontinence without indwelling or external urinary catheter
  • Advanced kidney disease at baseline defined as baseline eGFR \< 25 ml/min/1.73m2
  • Unexplained hypoglycemia in the past 30 days from enrollment
  • History of Fournier's gangrene (pelvic necrotizing fasciitis)

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (2 Sites)

  • Yale New Haven Hospital-St. Raphael Campus — New Haven, Connecticut
  • Yale New Haven Hospital — New Haven, Connecticut

📞 Contact the Study Coordinator

Phone: (203) 931-5064

Email: abinet.aklilu@yale.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Heart Failure

Explore by condition: All Heart Failure clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗